DRUG:NASDAQ
Bright Minds Biosciences Inc
$54.01
arrow_downward
-0.07%(-0.040) 1D
Oct 12, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
$53.89
High
$55.20
Low
$53.27
Mkt. cap
760.52M
Avg. vol.
114.89K
Volume
134.58K
52-wk high
$123.75
52-wk low
$47.35
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
Open
$53.89
High
$55.20
Low
$53.27
Mkt. cap
760.52M
Avg. vol.
114.89K
Volume
134.58K
52-wk high
$123.75
52-wk low
$47.35
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
News stories
From web sources and news partners
Stocktwits
·
1 hour ago
Big Banks Kick Off Q3 Earnings With S&P 500 Near Records — Strategists Flag What Could Move Markets
BigGo Finance
·
37 minutes ago
S&P 500 Bull Market Turns 4, AI Fuels 118% Surge—Rates Loom as Year 5 Hurdle
Cryptonews.net
·
53 minutes ago
Evernorth Hits Nasdaq With 473 Million XRP as XRPN Trading Begins
Yahoo Finance
·
8 hours ago
Not Sandisk, Not Intel. This Stock Will Lead the S&P 500 Next Year
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc